Liping Liu is Founder, CEO and Chairperson of HighTide Therapeutics Inc. (HighTide), a publicly listed biotech company (HKSE: 2511) specializing in developing multifunctional, multi-targeted therapies for metabolic and digestive diseases. The rising global incidence of metabolic disorders, including Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Steatohepatitis (MASH), has resulted in diminished life expectancy and productivity. The concurrent occurrence of T2DM and MASH is widespread, heightening the risk of disease progression and mortality. HighTide is discovering and developing novel treatments to meet the needs of patients with diverse comorbid conditions. The company’s current focus is advancing its lead compound, berberine ursodeoxycholate (HTD1801), for the treatment of T2DM and MASH. HighTide is currently engaged in a Phase 2b multi-regional clinical trial (CENTRICITY) evaluating HTD1801 in MASH patients with comorbid T2DM or pre-diabetes, and Phase 3 clinical trials in T2DM (SYMPHONY). Prior to establishing HighTide, Liping gained extensive experience in metabolic and digestive diseases through roles in drug discovery and development at US biotech companies, including Stealth BioTherapeutics, ATCC, and MannKind. Liping holds a doctoral degree from Nankai University, completed post-doctoral fellowship training at the University of Toronto and the Hospital for Sick Children, and earned an MBA from the Johns Hopkins Carey Business School.
Liping Liu
